Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Cialis committee?

Executive Summary

Lilly/ICOS's erectile dysfunction therapy Cialis is not scheduled for review at May advisory committee that will discuss Levitra's QT prolongation issues. Lilly says there has been no evidence of QT problems with Cialis, even in study patients dosed with up to 500 mg; the maximum dose being sought for approval is 20 mg. Like Levitra, Cialis is "approvable" at FDA and was recently approved in Europe. EMEA notes no cardiovascular effects were observed, but Lilly/ICOS "has committed to conduct a HERG channel assay with tadalafil as a post-authorization follow-up measure"...

You may also be interested in...



Flu Vaccine Leader Sanofi Joins Fight Against Covid-19

As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.

Sobi Reaps Benefits From Acquisitions, Commercial Focus

Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.

  

Medicare Plans Are Discouraging Generics Use

An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.

UsernamePublicRestriction

Register

PS041577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel